File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study

TitleSafety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study
Authors
Issue Date2009
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2009, v. 27 n. 43, p. 5936-5941 How to Cite?
AbstractThis study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix™) during the first 2 years of life in Asian infants from high-income countries. Healthy infants were enrolled to receive 2 doses of RIX4414 (N = 5359) or placebo (N = 5349). From 2 weeks post-dose 2 to 2 years of age, vaccine efficacy was 96.1% (95%CI:85.1%; 99.5%) against severe rotavirus gastroenteritis, 100% (95%CI:80.8%; 100%) against wild-type G1P[8] and 93.6% (95%CI:74.7%; 99.3%) against circulating non-G1 rotavirus types. No intussusception cases were reported within 31 days post-vaccination. RIX4414 shows a good safety profile and offers high protection during the first 2 years of life with potentially significant public health impact in this population. © 2009 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/170422
ISSN
2015 Impact Factor: 3.413
2015 SCImago Journal Rankings: 2.044
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorPhua, KBen_US
dc.contributor.authorLim, FSen_US
dc.contributor.authorLau, YLen_US
dc.contributor.authorNelson, EASen_US
dc.contributor.authorHuang, LMen_US
dc.contributor.authorQuak, SHen_US
dc.contributor.authorLee, BWen_US
dc.contributor.authorTeoh, YLen_US
dc.contributor.authorTang, Hen_US
dc.contributor.authorBoudville, Ien_US
dc.contributor.authorOostvogels, LCen_US
dc.contributor.authorSuryakiran, PVen_US
dc.contributor.authorSmolenov, IVen_US
dc.contributor.authorHan, HHen_US
dc.contributor.authorBock, HLen_US
dc.date.accessioned2012-10-30T06:08:26Z-
dc.date.available2012-10-30T06:08:26Z-
dc.date.issued2009en_US
dc.identifier.citationVaccine, 2009, v. 27 n. 43, p. 5936-5941en_US
dc.identifier.issn0264-410Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/170422-
dc.description.abstractThis study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix™) during the first 2 years of life in Asian infants from high-income countries. Healthy infants were enrolled to receive 2 doses of RIX4414 (N = 5359) or placebo (N = 5349). From 2 weeks post-dose 2 to 2 years of age, vaccine efficacy was 96.1% (95%CI:85.1%; 99.5%) against severe rotavirus gastroenteritis, 100% (95%CI:80.8%; 100%) against wild-type G1P[8] and 93.6% (95%CI:74.7%; 99.3%) against circulating non-G1 rotavirus types. No intussusception cases were reported within 31 days post-vaccination. RIX4414 shows a good safety profile and offers high protection during the first 2 years of life with potentially significant public health impact in this population. © 2009 Elsevier Ltd. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_US
dc.relation.ispartofVaccineen_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshGastroenteritis - Prevention & Control - Virologyen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshRotavirus Infections - Prevention & Controlen_US
dc.subject.meshRotavirus Vaccines - Administration & Dosageen_US
dc.subject.meshVaccines, Attenuated - Administration & Dosageen_US
dc.titleSafety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled studyen_US
dc.typeArticleen_US
dc.identifier.emailLau, YL:lauylung@hkucc.hku.hken_US
dc.identifier.authorityLau, YL=rp00361en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.vaccine.2009.07.098en_US
dc.identifier.pmid19679216-
dc.identifier.scopuseid_2-s2.0-70349431081en_US
dc.identifier.hkuros170390-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-70349431081&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume27en_US
dc.identifier.issue43en_US
dc.identifier.spage5936en_US
dc.identifier.epage5941en_US
dc.identifier.isiWOS:000271170500004-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridPhua, KB=7003538202en_US
dc.identifier.scopusauthoridLim, FS=7006112665en_US
dc.identifier.scopusauthoridLau, YL=7201403380en_US
dc.identifier.scopusauthoridNelson, EAS=35071611500en_US
dc.identifier.scopusauthoridHuang, LM=7404736430en_US
dc.identifier.scopusauthoridQuak, SH=35512093800en_US
dc.identifier.scopusauthoridLee, BW=7405437980en_US
dc.identifier.scopusauthoridTeoh, YL=6603277028en_US
dc.identifier.scopusauthoridTang, H=15828580700en_US
dc.identifier.scopusauthoridBoudville, I=6507808395en_US
dc.identifier.scopusauthoridOostvogels, LC=34768573900en_US
dc.identifier.scopusauthoridSuryakiran, PV=26022588400en_US
dc.identifier.scopusauthoridSmolenov, IV=23499725700en_US
dc.identifier.scopusauthoridHan, HH=8545352800en_US
dc.identifier.scopusauthoridBock, HL=7201825902en_US
dc.identifier.citeulike5432708-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats